Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 8, 2025
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 8, 2025
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential …
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort …
Theriva Biologics anuncia el precio de su oferta pública de 7,5 millones de dólares
GlobeNewswire
·
May 8, 2025
ROCKVILLE, Maryland, May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha …
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
GlobeNewswire
·
May 8, 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS …
Axogen, Inc. Reports 2025 First Quarter Financial Results
GlobeNewswire
·
May 8, 2025
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights …
Wellgistics Health Secures $50M Credit Facility and Launches XRP-Powered Payment Initiative
GlobeNewswire
·
May 8, 2025
Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based …
LENSAR Reports First Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the …
Seamless Therapeutics Expands Board of Directors with Appointment of Alvin Shih
GlobeNewswire
·
May 8, 2025
Dresden, Germany, and Lexington, MA, May 8, 2025 – Seamless Therapeutics, today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is an experienced drug developer and physician with a track record of …
ProQR Announces First Quarter 2025 Operating and Financial Results
GlobeNewswire
·
May 8, 2025
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer …
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
GlobeNewswire
·
May 8, 2025
HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
May 8, 2025
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical …
Apyx Medical Corporation Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last year U.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last year Preparing for a planned launch of the AYON™ Body …
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in …
Shock Top: A Bold Rebrand for a Craft Beer Icon
GlobeNewswire
·
May 8, 2025
PORTLAND, Ore., May 08, 2025 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), known for its bold flavors and unfiltered wheat ales, today announced a transformative rebrand. With …
Microbix Schedules Release of Results for Q2 Fiscal 2025
GlobeNewswire
·
May 8, 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure …
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 8, 2025
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership …
Ligand Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $ …
Syndax Announces Participation in May Investor Conferences
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as …
Aptose Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat …
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
GlobeNewswire
·
May 8, 2025
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, …